Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + irinotecan
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab + irinotecan is a combination therapy used primarily in oncology. Bevacizumab is a recombinant humanized monoclonal antibody that targets and neutralizes vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis and reducing tumor vascularization. Irinotecan is a small molecule chemotherapeutic agent classified as an antineoplastic; it inhibits topoisomerase I, leading to DNA damage and cell death in rapidly dividing cancer cells. This combination has been studied and used for the treatment of advanced colorectal cancer (often with other agents such as fluorouracil and leucovorin) and recurrent malignant glioma. The addition of bevacizumab to irinotecan-based regimens can improve response rates but may increase certain toxicities such as diarrhea, leukopenia, hemorrhage, thromboembolic complications, and gastrointestinal side effects[1][3][4][8].
- Other names
- rhuMab VEGFCPT-11CPT11CPT 11
02
Targets
TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + irinotecan.